Rivaroxaban - Prevention of atherothrombotic events - Acute Coronary Syndrome
You are here : Home > Formulary Search > Rivaroxaban - Prevention of atherothrombotic events - Acute Coronary Syndrome
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Documentation
NICE Technology Appraisal
Evidence Review
PAD Profile
ChemicalSubstance :
Rivaroxaban
Indication :
Prevention of atherothrombotic events - Acute Coronary Syndrome
Group Name :
Keywords :
Acute Coronary Syndrome, anticoagulant cards, anticoagulant alert cards
Brand Names Include :
Xarelto
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2
Other Indications
Below are listed other indications that Rivaroxaban is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Prevention of atherothrombotic events - Acute Coronary Syndrome.
Committee Recommendations (2)
01 Jun 16 -
Surrey Medicines Commissioners Group
Surrey Medicines Commissioning Group recommend that patients prescribed all types of anticoagulants (warfarin and NOACs) should be given an anticoagulant alert card to carry with them. For patients taking NOACs, the card should be annotated on the reverse in the “Therapeutic range (INR)” box with the words “not applicable” or “not required for this drug”.
The cards are available for practices to order through usual NHS stationery supply routes.
See an example of the Anticoagulant Alert Card in the document below
The cards are available for practices to order through usual NHS stationery supply routes.
See an example of the Anticoagulant Alert Card in the document below
The PCN supports the use of rivaroxaban as a treatment option in combination with clopidogrel plus aspirin, or aspirin alone, for preventing adverse outcomes after acute management of acute coronary syndrome.
To ensure safe implementation of NICE TA335 Acute Trusts need to update their ACS pathway to include rivaroxaban as a treatment option and this should be agreed by the Trust’s DTCs.
To ensure safe implementation of NICE TA335 Acute Trusts need to update their ACS pathway to include rivaroxaban as a treatment option and this should be agreed by the Trust’s DTCs.